Form 4: Astrana Health Director Mitchell Kitayama Receives Equity Grant

Astrana Health, Inc. Director Mitchell W. Kitayama was granted 6,449 shares of common stock under the company's 2024 Equity Incentive Plan, increasing his total beneficial ownership to 21,060 shares.

Summary

• Mitchell W. Kitayama, a Director of Astrana Health, Inc. (ASTH), acquired 6,449 shares of the company's common stock.
• The acquisition occurred on June 11, 2025, and was a grant of restricted shares with a price of $0 per share.
• These shares were granted pursuant to the Issuer's 2024 Equity Incentive Plan.
• The 6,449 restricted shares will vest on the earlier of June 11, 2026, or the date of Astrana Health's 2026 annual meeting of stockholders.
• Following this transaction, Mr. Kitayama's total beneficial ownership of Astrana Health common stock is 21,060 shares.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it represents a standard equity grant to a director, aligning their interests with shareholders. It's a routine compensation event rather than a significant market-moving announcement.

Positives

• The equity grant aligns the interests of Director Mitchell W. Kitayama with those of Astrana Health's shareholders, incentivizing long-term performance.
• The grant is part of a pre-existing 2024 Equity Incentive Plan, indicating a structured approach to executive and director compensation.

Future Outlook

The 6,449 restricted shares granted to Director Mitchell W. Kitayama are scheduled to vest on the earlier of June 11, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, indicating a future milestone for the compensation.

Industry Context

This transaction is a routine insider filing (Form 4) reporting a director's acquisition of company stock, typically part of an equity compensation plan. Such grants are common practice across industries to align management and director incentives with shareholder value creation.

Corporate Governance

Related Party Transactions

• Grant of 6,449 shares of common stock to Director Mitchell W. Kitayama, a related party, under the Issuer's 2024 Equity Incentive Plan.

Stakeholder Impact

• Shareholders: The grant of restricted stock to a director aims to align management incentives with shareholder interests, potentially leading to improved long-term performance.
• Employees: While this specific grant is to a director, the existence of an Equity Incentive Plan suggests a broader framework for employee and executive compensation.

Next Steps

• Vesting of the 6,449 restricted shares on the earlier of June 11, 2026, or the date of the Issuer's 2026 annual meeting of stockholders.

Key Dates

Keywords

Astrana Health, ASTH, Mitchell W. Kitayama, Director, Equity Grant, Restricted Stock, SEC Form 4, Insider Transaction, Stock Ownership, Equity Incentive Plan